Testing new clotting factor for people with untreated or minimally treated Hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Hemophilia A that is severe (very low factor activity: FVIII below 1%)
- You (or your doctor) have already decided to start an Octapharma FVIII treatment before joining the study
- You either have never received FVIII clotting factor before, or have had fewer than 5 exposure days
- You have no history of an inhibitor to FVIII (an immune reaction that blocks the medicine), or you developed one only while using Octapharma FVIII and can continue it
- You are able to give informed consent (or a parent/legal guardian can sign for you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This trial tests a new factor VIII treatment (SKP-0141) for severe hemophilia A. It aims to see if it can prevent or treat bleeding episodes, replacing standard factor VIII therapy.
This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.